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Abbreviations 
 BC, breast cancer; CDX, CTCs-derived xenograft; CTCs, Circulating Tumor cells; ER, estrogen 
receptor; FFPE, Formalin-fixed paraffin-embedded; GO, gene ontology; HER2, Human 
Epidermal growth factor-2; M1, metastatic site 1; M2, metastatic site 2; N, healthy or normal 
tissue; PBMCs, peripheral blood mononuclear cells; PCA, principal component analysis; PDX, 
primary tumor derived xenograft; PR, progesterone receptor; PT, primary tumor; RT-PCR, Real 
time-PCR; TNBC, Triple negative breast cancer; V1, Visit 1 (before treatment); V2, Visit 2 (after 
treatment). 
Article category: Tumor Markers and Signatures 
Novelty and Impact 
This work describes for the first time the development of a CTCs-derived xenograft (CDX) from 
a patient with metastatic Triple Negative Breast Cancer, laying on the table the usefulness of 
this type of approach in the field of liquid biopsy. This study has allowed the identification of 
prognostic markers and therapeutic targets in CTCs from TNBC patients. The potential clinical 
translation of the results makes it extremely interesting for oncologists and patients with a 





















Triple-negative breast cancer (TNBC) is characterized by high rates of metastasis and no 
available molecular targets. CTCs derived xenografts (CDX) have demonstrated to be a 
promising tool for understanding cancer biology. In this study a CDX from a TNBC patient was 
developed for the first time. After CDX characterization, WNT signalling was found as the main 
mechanism related with this tumor biology and potential CTCs markers were identified and 
subsequently validated in TNBC patients. In this cohort high levels of MELK expression were 
associated with poorer survival rates. Overall, this study demonstrates that CTCs from TNBC 
are tumorigenic and CDXs are a useful model to obtain valuable information about the tumor. 
Introduction  
Triple Negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer (BC) 
that represents 10-20% of all the cases 1, which is characterized by a lack of both estrogen 
receptor (ER) and progesterone receptor (PR) expression, and non-amplification of the Human 
Epidermal growth factor-2 (HER2), which hinders the choice of standard therapy. Depending 
on its staging TNBC patients are treated with a combination of surgery, chemotherapy and 
radiation. Heterogeneity of TNBC and the quick development of resistance, greatly limit the 
clinical benefits of many therapies, explaining their high rate of metastatic disease and their 
poor overall survival. Consequently, it is essential to delve into the biology of this BC subtype 
to identify new potential therapeutic targets that can lead to effective treatments. The 
integration of basic, preclinical and clinical research is the best way to reach it.  
In vivo models have a great potential for basic and preclinical cancer research directed to the 
discovery of biomarkers, the understanding of drug resistance mechanisms and the 
development of new therapies. In fact,  efforts to use PDX (primary tumor derived xenograft) 
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retain morphologies, architectures and molecular signatures very similar to those of the 
original tumors 2.  
Normally, both tumor molecular characterization and PDX generation are based on tissue 
biopsies from the primary tumor. However, the opportunity to gain insight into circulating 
tumoral elements opens a new perspective for tumor characterization. In this sense, it is 
important to remark that cells dissemination from the primary tumor through the bloodstream 
as circulating tumor cells (CTCs) is a critical step for the metastasis formation. The enumeration 
of CTCs has been associated with the clinical outcome in both early and advanced BC patients 
in a high number of studies 3–8. CTCs changes, evaluated during treatment, turned to be a 
reliable surrogate marker of response to treatment. Importantly, CTCs are considered a 
valuable “liquid biopsy” because they represent the most aggressive tumor population, being a 
useful model to study the tumor biology at real time, before and during treatment. Despite 
their potential, there are still technical limitations regarding the molecular characterization 
and the ex vivo expansion of CTCs, mainly due to their scarcity and low viability in circulation.  
Transient CTCs primary cultures from metastatic BC patients were obtained9 10 but, until now, 
only two groups were able to generate CDX (CTCs-derived xenograft) from BC patients, 
demonstrating the feasibility to expand these cells in vivo and their tumorigenic potential 11,12. 
Despite these hopeful results obtained in breast tumors, in vivo expansion of CTCs from TNBC 
patients has not been reached so far.  
Here, we describe for the first time the generation of a CDX model from a metastatic TNBC 
patient, showing the tumorigenic capability of the CTCs population in this patient. CDX 
molecular characterization provides a unique tool to enhance our understanding of the main 
pathways implicated in TNBC evolution and dissemination, and to identify interesting 
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Materials and Methods.  
Patients  
A total of 32 patients diagnosed of TNBC at Complexo Hospitalario Universitario of Santiago de 
Compostela were included in the study (Supplementary Table I). In addition, 22 age matched 
healthy controls were also included. All participants signed an informed consent specifically 
approved for this study by the Galician Investigation Ethical Committee (code of approval: 
2013/462). 
Clinical samples 
Two tubes (7.5 mL) of peripheral blood were obtained from each patient: one EDTA vacutainer 
(Becton Dickinson) for CTCs enrichment and characterization, and one CellSave Preservative 
tube (Menarini, Silicon Biosystems Inc), for CellSearch enumeration. In patients with clear 
progressing disease, we obtained a second sample, visit 2 (V2). 
In patient #20, a 43 years old woman with high CTC counting (969 CTCs/7,5mL) at V2, an 
additional EDTA blood tube (7.5 mL) was obtained for CDX generation (Figure S2). Formalin-
fixed paraffin-embedded (FFPE) biopsies from this patient’s primary tumor (obtained at 
baseline, before surgery and chemotherapy) and metastasis after disease progression were 
provided by the Pathology Service and the BioBank of Complexo Hospitalario Universitario de 
Santiago (CHUS) (PT17/0015/0002), integrated in the Spanish National Biobanks Network. 
These samples were processed following standard operating procedures with the appropriate 
approval of the Ethical and Scientific Committees. 
CTC enumeration and characterization. 
CellSave tube was analyzed for CTCs enumeration by the CellSearch System, using CellSearch 
Epithelial Circulating Tumor Cell Kit (Menarini, Silicon Biosystems Inc); EpCAM enriched cells 
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allophycocyanin (APC) conjugated anti-CD45 antibodies and with 4,6-diamino-2-phenylindole 
(DAPI) to identify the nucleus. The CellTracks Analyzer (Menarini, Silicon Biosystems Inc) was 
used to acquire digital images of the 3 different fluorescent dyes using a 12-bit camera which 
were reviewed by trained operators in order to determine the CTCs count. 
EDTA tube was used for EpCAM+ isolation of CTCs (CELLectionTM Epithelial Enrich Kit, Thermo 
Fisher Scientific) according to manufacturer’s instructions. CTCs coupled to the magnetic beads 
were resuspended in 100 µl of RNAlater (Ambion) and stored at -80ºC until RNA extraction. 
Mice 
Mice experimental protocols were approved by the Ethical Committee of the University of 
Santiago de Compostela (15010/2015/001). Mice were held in our animal facility at the Center 
for Research in Molecular Medicine and Chronic Diseases (CIMUS, Santiago de Compostela) 
and given food and water ad libitum, in accordance with CIMUS guidelines (ES150780275701). 
NMRI-Foxn1nu/nu was obtained from Janvier Lab (France) and Scid beige mice (RRID: 
IMSR_CRL:250) were obtained from the Barcelona Biomedical Research Park (PRBB, 
Barcelona). After mice arrival, at least one week of acclimation was considered.  
CDX establishment & follow-up  
For CDX establishment, isolation of peripheral blood mononuclear cell fraction (PBMCs) was 
performed by density gradient centrifugation protocol (Histopaque®-1077, Sigma) in 
SepMate™ tubes (StemCell Technologies) according to manufacturer´s instructions. The 
recovered cells were diluted 1:2 with Matrigel Matrix (Corning) and implanted subcutaneously 
into a NUDE mouse. After cell injection, the mouse was followed up weekly for tumor 
development using XenoLight RediJect 2-DG-750 (Perkin Elmer) by Xenogen IVIS 200 system; 
briefly, 100 µl of the reagent were injected intraperitoneally and the fluorescence was read 3 
hours later. Five months after cell injection, a macroscopic tumor was observed; mouse was 
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explant (25%) was implanted subcutaneously into a Scid Beige mouse (CDX2), and another 
piece (25%) was mechanically disaggregated and culture in RPMI media in suspension. After 13 
days of culture, cells were collected and injected into the mammary fat pad of a Scid Beige 
mouse (CDX2M). Tumor growth was monitored by in vivo image weekly; CDX2 was euthanized 
two months after cell injection, and CDX2M after three and a half months. CDX-derived tumor 
tissue fragments were collected from necropsied animals into RNAlater (Ambion) and stored at 
−80°C. 
CTCs analyses from mice blood 
Blood extraction was performed by cardiac puncture using 4 mL EDTA tubes. CTCs 
enumeration was carried out using CellSearch Technology (Menarini, Silicon Biosystems Inc) 
from 150 μl of mouse blood mixed with 25 μl of human healthy blood (essential for the correct 
autofocus of the sample). The volume-scaled protocol for isolation and immunostaining was 
performed manually using CellSearch Epithelial Circulating Tumor Cell Kit (Menarini, Silicon 
Biosystems Inc). Digital images acquisition was performed as described before.   
RT-qPCR 
CTCs 
Total RNA from CTCs was extracted with the QIAmp viral RNA mini kit (Qiagen). Reverse 
transcription was performed with SuperScript III (Invitrogen) following manufacturer’s 
instructions. RT-PCR analysis was performed as described by Barbazán et al.13 for a customized 
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CDX tumors & FFPE tissue  
CDX tumors were disaggregated with Tissuelyser (Qiagen) and RNA extraction performed with 
AllPrep DNA/RNA Mini Kit (Qiagen) following the manufacturer's instructions. Reverse 
transcription was performed with SuperScript III (Invitrogen). 
Total RNA from FFPE tissue sections was extracted using the miRNeasy FFPE kit (Qiagen). cDNA 
was synthesized with MulV retrotranscriptase chemistry (Applied Biosystems) following 
manufacturer’s instructions. RT-qPCR analyses were performed in healthy, tumoral and 
metastatic tissue. Samples were preamplified with TaqMan PreAmp Master Mix (Applied 
Biosystems) with 14 reaction cycles.  
cDNA expression was  analyzed on a LightCycler 480 II (Roche Diagnostics) with TaqMan Gene 
Expression Master Mix and TaqMan probes (Applied Biosystems) for a customized panel of 12 
genes in the FFPE tissue and 22 genes in the CDX tumors.  GAPDH and B2M were used as 
reference genes in the FFPE samples and CDX tumors respectively.  
Gene expression heatmap was obtained using R software (version 3.4.4.). 
Immunohistochemistry 
FFPE mouse tissue blocks were sectioned at 3 μm, dried for 1h at 65ºC before pre-treatment 
procedure of de-paraffinization, rehydration and epitope retrieval in the Pre-Treatment 
Module, PT-LINK (DAKO) at 95 °C for 20 min in 50x Tris/EDTA buffer, pH 9 and endogenous 
peroxidase was blocked.  The antibodies used recognizes KI67 (1:100, clone SP6), Wide 
Spectrum Cytokeratin (1:100, Polyclonal), CD45 (1:100, clone EP322Y), ER (1:100, clone SP1), 
PR (1:100, clone YR85), ECAD (1:100, clone EP700Y), ALDH1A1 (1:100, Polyclonal) (ABCAM, 
Cambridge, UK); N-Cadherin (1:100, clone EPR1792Y, Merk Millipore, USA), SNAI 1 (1:100, 
clone H-130), EP-CAM (1:50, clone H70, (Santa Cruz Biotechnology, Dallas, USA), c-erbB-2 
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incubation of the primary antibody, the reaction was visualized with Biotin-SP-AffiniPure Goat 
Anti-Rabbit IgG (1:200, Jackson ImmunoResearch, Jennersville, USA), and Streptavidin (1:400, 
Agilent Technologies-DAKO, Santa Clara, United States) using diaminobenzidine chromogen as 
a substrate. Sections were counterstained with haematoxylin. Appropriate negative controls 
including no primary antibody were also tested. 
The Ki67 percentage was automatically measured using an ACIS® III Instrument (Dako, 
Denmark, Glostrup). A percentage ≥ 14% was considered as high expression.  
RNA-Sequencing Analysis.  
Samples were barcoded and prepared for sequencing at the Wellcome Trust Centre for Human 
Genetics, Oxford, where 75 bp paired-end (PE) reads were obtained on an Illumina HiSeq 4000. 
The raw data has been deposited in the NCBI’s Sequence Read Archive (SRA) under accession 
number (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA464335). The quality of the 
sequencing output was assessed using FastQC v.0.11.5 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Quality filtering and removal 
of residual adaptor sequences was conducted on read pairs using Trimmomatic v.0.35 14. 
Specifically, Illumina adaptors were clipped from the reads, leading and trailing bases with a 
Phred score < 20 were removed and the read trimmed if a sliding window average Phred score 
over four bases was less than 20. Only reads where both PE reads had a length greater than 36 
bp post-filtering were retained. Filtered reads were mapped to the human genome 
(GRCh38.p10) and the mouse genome (GRCm38.p5) using STAR v.2.5.2b 15, the maximum 
number of mismatches for each read pair was set to 10 % of trimmed read length, and 
minimum and maximum intron lengths were set to 20 bases and 1 Mb respectively. For those 
reads aligning to both the human and the mouse genome, only those with a higher mapping 
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Paired-reads uniquely mapped to the human genome were counted and assigned to genes 
using FeatureCounts 16, included in the SourceForge Subread package v.1.5.0. Only reads with 
both ends mapped to the same gene were retained. Gene count data were used to estimate 
differential gene expression using the Bioconductor packages DESeq 2 v.3.4 17. Samples were 
hierarchically clustered according to gene read counts after a variance stabilizing 
transformation, using Euclidean as the distance measure and complete-linkage as the 
agglomeration method (R package flashClust18). Heatmaps of gene expression were created 
using the R package gplots v3.0.1 heatmap.2 function, using read counts after regularized log 
transformation (DESeq217). 
The Genome Analysis Toolkit (GATK) framework was used for variant calling. Duplicated reads 
were removed using Picard v.1.128 (http://broadinstitute.github.io/picard). GATK19  was used 
to remove sequences overhanging into the intronic regions, to reassign STAR mapping qualities 
to default values and to perform base quality score recalibration. Somatic SNPs and Indels 
were identified using Mutect2, which combines the original MuTect20 and HaplotypeCaller 19. 
The mutations were annotated using Variant Effect Predictor (Ensembl version 9021).  
Enrichment analysis of Gene Ontology terms was done upon uploading selected probe sets 
identifiers into GSEA (Gene Set Enrichment Analysis) and Panther web tools.  
Statistical Analysis.  
Data was analyzed using IBM SPSS Statistics for Macintosh, Version 22.0 (SPSS Inc., Chicago) 
and GraphPad Prism 6.01 software (GraphPad Softwares Inc, San Diego). Gene expression 
differences between patients and controls were analyzed using Mann-Whitney test. PFS and 
OS were analyzed using Kaplan-Meier analysis and differences were examined by log-rank test. 
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Molecular profiling of CTCs during tumor evolution 
One patient with advanced TNBC (Patient #20) was selected for CDX generation because she 
presented a high CTC count after CellSearch analysis (969 CTCs/7,5mL). A longitudinal study 
was carried out throughout the disease evolution of this patient (Figure 1 and M&M). Samples 
were collected at two different time points of the disease to perform CTCs molecular 
characterization by RT-qPCR which included a panel of genes related with epithelial (EpCAM, 
ECAD, EGFR, CRIPTO), mesenchymal (VIM, SNAI1) and stem cell (ALDH1, CD49f) features, 
together with tumor progression associated genes (CD44, BCL11A or AR). CTCs enumeration by 
CellSearch was 5 CTCs and 969 CTCs/7,5mL in Visit 1 (V1) and Visit 2 (V2), respectively. Figure 2 
shows the expression level of the analyzed genes in both CTCs and tumoral tissues (primary 
tumor and lymph node metastasis). VIM and CD44 showed high expression in all samples while 
EGFR and AR had low levels. CTCs express higher levels of CRIPTO1 and TIMP1 than tissue 
samples, while the contrary occurs for SNAI1 expression. CD49f, EpCAM and ECAD increased 
their expression levels in V2 when comparing with V1. However, when comparing CTCs with 
tissue samples, EpCAM expression is higher in primary tumor while ECAD expression in V2 is 
comparable with metastatic samples. In CTCs samples KRT19, TWIST and CTNNB1 were over-
expressed in V2 compared with V1 (data not shown). 
CTCs-Derived Xenograft development from a TNBC patient is representative of primary 
tumor 
In order to get a TNBC CDX development, the PBMCs fraction (with low percentage of CD45+ 
cells, data not shown) was injected in an immunocompromised mouse (CellSearch 
enumeration = 969 CTCs, including 74 CTCs clusters (from 2 to 7 cells) (Figure S1)) and 5 
months later mouse was sacrificed and tumor was removed (CDX1) (Figure 3). Part of the 
tumor was subsequently passaged to 2 Scid Beige mice (CDX2, CDX2M) (see M&M, Figure 
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mouse sacrifice and analyzed by CellSearch detecting a CTCs cluster (Figure 3C), which reveals 
the invasiveness potential of these tumor cells. The pathology analysis disclosed that the three 
CDX tumors were poorly differentiated carcinoma specimens with high proliferative activity 
(high ki67 expression: 40% in CDX1, CDx2 and CDX2M). This matched with the primary tumor 
molecular features: negative for CD45, ER and PR expression and positive for pan-
cytokeratines and ECAD (Figure 4A, Figure S2). Expression for EpCAM, N-CAD, ALDH1A1 and 
SNAI1 was also observed (Figure 4A, Figure S2). Gene expression profile of CDX samples was 
performed by RT-qPCR to determine similarity among tissue and CTCs samples (Figure 4B) and 
to check if tumor passaging modifies the genomic profile (Figure S2). Most of the analyzed 
genes did not change through the passages but it was observed a decrease in AR, ECAD, EGFR 
and CCND1 expression rate on the second generation mice. An increase in the expression of 
VIM and a decrease in the expression of CRIPTO1 were observed in CDX2M and CDX2 
respectively.  
WNT pathway role in tumor progression in the CDX case 
RNA sequencing analysis was performed to determine whether CDX samples shared molecular 
characteristics with patient samples and to identify potential pathways involved in tumor 
progression in TNBC. For that, healthy or normal tissue (N), primary tumor (PT) and two 
different metastatic sites (M1 and M2: lymph nodes) from FFPE samples and CDX samples 
(fresh tissue) were included. First, primary tumor was compared with healthy tissue and, after 
removing lowly expressed genes (<100 reads), genes showing a log2 Fold Change |2| were 
selected as specifically altered due to tumoral transformation (Supplementary Table II). These 
genes behaviour in all samples was interpreted using a heatmap (Figure 5A), and a principal 
component analysis (PCA) was carried out to understand how the tumor samples clustered 
based on their differences with the control (Figure 5B). CDX samples grouped together near 
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obtained from this analysis (Supplementary Table II).  Venn graph, which shows those genes 
shared among samples, is represented in Figure 6 and S3. Thus, CDX tissues have 1080 up-
regulated genes in common among the three tumors (CDX1, CDX2 and CDX2M) (Figure S3A). 
M1 and M2 showed 1235 (36.3%) common up-regulated genes (Figure S3B). Then, those 
common genes were compared between CDXs and metastasis, finding 433 (23%) mutual genes 
(Figure 6A). We also found 1706 (71.9%) common down-regulated genes in CDX tumors (Figure 
S3C), while 1079 (45.5%) down-regulated genes were shared between metastatic samples 
(Figure S3D). Comparative analysis of common genes inferred 823 (41.9%) mutual genes 
(Figure 6C).  
Amongst up-regulated genes in both metastasis and CDX (433), cell cycle genes were strongly 
represented (Figure 6B), while down-regulated genes (823) accounted for different general cell 
functions such as system process or tissue development (Figure 6D).  
Next, we performed a gene ontology analysis (GO). We included the up-regulated genes from 
all samples compared to normal tissue. Amongst those genes, WNT signalling was the main 
pathway involved in the biology of all samples (Figure S4). Further, GO analysis was performed 
considering the common genes between CDX, metastasis and both. Again, WNT pathway was 
the most represented followed by cadherin signalling pathway (Figure 7). Regarding down-
regulated genes, GnRH, inflammation and WNT pathway stood out (data not shown).  
SNPs analysis demonstrated that the three CDXs were very homogeneous since they share 
68.4% of the deleterious polymorphisms found (Figure S5A). This group of common SNPs was 
selected for comparison with the other samples, showing important tumor heterogeneity 
among them, especially marked between M1 and M2, which only share 1,4% (Figure S5B). 
While these metastases only share 3 SNPs with the primary tumor, the CDXs samples have 13 
SNPs in common with it. There was only one deleterious mutation shared by all the analyzed 
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MELK: a prognostic marker for TNBC identified from CDX molecular characterization 
A panel of genes was selected for a further validation based on their representation of the 
main pathways identified by GO analysis (Figure 7 and Figure S4), their expression level in RNA-
seq analysis and their involvement in breast cancer development. Genes were analyzed by RT-
qPCR in an EpCAM positive CTCs population isolated from the V1 and V2 in patient #20.  Gene 
expression of the 5 selected genes (AURKB, HIST1H4A1, MELK, MYCL and PCDHA8) was 
detected in both sampling points (data not shown). Lastly, we analyzed these genes in CTCs 
from the cohort of TNBC patients (n=32, which includes patient #20) and healthy donors 
(n=22). The AURKB, HIST1H4A1, MELK and PCDHA8 genes were more expressed in patients 
than in controls (p < 0.05) (Figure 8A) demonstrating their presence in the CTC population. In 
addition, we explored the prognostic potential of our CTCs markers by Kaplan–Meier survival 
analysis (Supplementary Table III) and we found that MELK overexpression was statistically 
associated with shorter PFS and OS rates (Figure 8B, C, Supplementary Table III). Besides, 
although differences were not statistically significant, patients with high levels of AURKB, 
HIST1H4A1 and PCDHA8 showed also lower survival rates. 
Discussion 
TNBC subtype is the most challenging among BC tumors due to its aggressive nature, high 
metastatic potency and lack of targeted therapy. Thus, there is an urgent need to understand 
the underneath mechanisms involving TN tumors development, which will lead to 
improvements in the clinical management of these patients. We attempted to tackle this 
challenge by analysing CTCs in TNBC patients. Importantly, we generated for the first time a 
CDX from one TNBC patient with high number of CTCs and CTCs clusters. Thus, contrary to a 
previous work 22, we demonstrated that CTCs from a TNBC patient are tumorigenic and 
constitute an attractive in vivo model to obtain a better understanding of the tumor biology. 
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Similarly, RNA-Seq analysis also demonstrated that CDX had a common origin with the tumor 
samples from the patient, confirming that CTCs isolated from blood were tumorigenic, since 
they were able to reproduce a tumor in a mouse model and subsequent passages. CDX tumors 
also had metastatic capacity, evidenced by the detection of CTCs in mouse blood. In addition, 
the detection of CTCs clusters in mouse blood supports the metastatic potential of these cells.   
We analyzed different tumor and blood samples over time, from both patient and the CDX, in 
order to perform a molecular tracking of the disease. Thus, we detected molecular changes 
among the primary tumor and the metastasis sites as well as among CTCs (V1 and V2), showing 
the relevance of liquid biopsy monitoring as a valuable tool for understanding tumor evolution. 
In addition, when CDX and CTCs are compared (V2) there is concordance in the gene 
expression of BCL11, CD49f, CRIPTO1, ECAD or VIM. The expression of this set of genes, that 
involved in stem and mesenchymal characteristics, represents a similar phenotype to that 
observed in patients with TNBC, which despite being an epithelial tumor type has a high 
mesenchymal phenotype. It is worth mentioning that the expression level of the analyzed 
genes is not entirely comparable among CTCs and CDX samples as CTCs were obtained using an 
EpCAM positive enrichment while CDX samples come from a population of CTCs that 
comprises EpCAM + and EpCAM–  CTCs after in vivo development.  
In addition, the analysis of the CDX allowed us to identify key molecular mechanisms involved 
in TNBC development that could be important therapeutic target. Thus, GO analysis pointed to 
the WNT pathway as the main underlying signalling up-regulated in all analyzed samples. WNT 
has been associated previously with a higher risk of metastasis and worse prognosis in TNBC 
patients 23,24. In addition, in vitro studies have shown that WNT pathway is preferentially 
activated in TNBC subtypes, and may represent a possible therapeutic target to treat this type 
of cancers 25. Importantly, WNT/β-catenin status identifies patients who are most likely to 
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isolated in the V2 (more advance disease) compared to V1, and in the three CDX generated 
from those CTCs, with more than two-fold expression compared with healthy tissue. In 
addition to the WNT pathway, up-regulated common genes among CDX samples and 
metastasis samples were mainly involved in cell cycle regulation, in accordance with the high 
proliferative activity required to form new tumor locations.  
Comprehensive data analyses led to the identification of highly expressed genes on all tumor 
tissue samples, suggesting their important relevance in tumor progression in #20 patient. 5 
selected genes were further analyzed in CTCs isolated from this patient and in CTCs from a 
TNBC patient´s cohort formed by 32 cases, demonstrating that AURKB, HIST1H4A1, MELK and 
PCDHA8 can be used to detect the presence of CTCs, and therefore, their potential value as 
indicators of tumor dissemination.  
These identified genes have distinct roles in BC development, including TNBC subtype. AURKB 
is a mitosis-related serine/threonine kinase that is overexpressed in various tumor types 
including TNBC 27,28. Elevated AURKB expression contributes to chemoresistance and predicts 
poor prognosis in BC patients 29, which has led to the development of AURKB inhibitors as 
anticancer drugs 30,31. In this regard, the option of monitoring AURKB expression in CTCs from 
TNBC patients could be an alternative for selecting this type of targeted therapy. Concerning 
the other analyzed markers, HIST1H4A is a histone cluster member of H4 family and plays a 
central role for transcription regulation, DNA repair, DNA replication and chromosomal 
stability. Lai and colleagues verified that acetylation of histone H4 induces cell apoptosis and 
growth arrest via inhibiting AKT signalling in hepatocellular carcinoma 32, however, little is 
known regarding its role in other tumor types, including TNBC.  
PCDHA8 gene is a member of the protocadherin alpha gene cluster. These neuronal proteins 
are cadherin-like cell adhesion proteins and have a role in the establishment and functioning of 
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of genes or cellular function, have still to be discerned. PCDHA8 is also involved in WNT 
pathway and has been suggested as a potential marker for the prediction of BC classification 
and staging of since it was part of a set of genes identified in a computational analysis of 
tissue-based gene expression data to identify possible gene signatures and markers of blood or 
urine proteins 34. We found this gene expressed in CTCs isolated from TNBC patient´s blood 
samples, however, little is known about its involvement in tumor development or metastasis. 
Novak and colleagues identified that the PCDHA family preserves aberrant hypermethylation 
in BC being the overall decrease in the expression of these genes correlated with the increase 
in the CpG islands methylation of PCDH cluster. This could be due to the disruption of the 
function of the transcription factors and the regulators of genes involved in the control of their 
expression35. Our results in CTCs support these evidences since we found a reduction in 
PCDHA8 expression as the disease progressed, probably due to methylation process.  
Finally, MELK has been described as an important kinase for the development process and has 
been implicated in mitotic progression, proliferation, apoptosis, differentiation, stem cell 
phenotypes, and tumorigenesis 36–39. This gene has been associated with various types of 
cancer, particularly aggressive malignancies 40, including TNBC 41–43. In fact, MELK has been 
described as one of 22 kinases overexpressed in TNBC when compared with other BC 
subtypes, and it was also functionally validated in vitro 41. A study using the BC data set of The 
Cancer Genome Atlas showed that MELK expression was eightfold higher in tumors than in 
normal breast tissue. In addition, MELK expression correlates with metastatic recurrence and 
increased mortality indicating that MELK may be predictive of BC metastasis and overall 
survival rate 44. Hence, we found that CTCs from TNBC patients express MELK, high levels being 
associated with lower OS and PFS rates, meaning a difference of 27.25 and 17.7 months, 
respectively. Regarding CTCs assays, a recent publication described MELK expression in spiked 
assays using TNBC cell line MDA-MB-231 45, however, these are not real CTCs. Other work 
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metastatic breast patients using AdnaTest EMT-1/Stem CellSelect kit 46, reinforcing our results. 
To our knowledge this is the first time that MELK expression measured in CTCs is correlated 
with OS or PSF in TNBC patients. Therefore our work marks a milestone pointing MELK as a 
potential survival marker detected by liquid biopsy, and also a potential therapeutic target 
with the additional value of already having active MELK inhibitors 47. 
Taking into account the interesting results obtained for AURKB, HIST1H4A1, MELK and 
PCDHA8, further studies should focus on these molecules and their role as tumor markers as 
well as their implication in tumor biology and tumor dissemination of TNBC subtype. 
In conclusion, we integrated CTCs analysis, CDX generation and RNA-Seq technology as a 
valuable strategy to delve into TNBC biology, providing clinicians with new potential 
therapeutic targets and markers to improve the clinical management of these patients. We 
described for the first time a CDX generation from a TNBC patient demonstrating that CTCs 
from these patients could be tumorigenic in mice. Although CDX generation can not be 
considered a general approach to improve patient care, it has a great value for translational 
research, as we have demonstrated. Characterizing the original tumor, the metastasis and the 
CDX we also confirmed the important role that the WNT pathway plays in TNBC, and identified 
a panel of markers that can be monitored in CTCs from these patients, providing important 
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Figure Legends 
Figure 1. Patient timeline and clinical case presentation, including the different samples 
analyzed in our study. M1: Metastasis site 1. M2: Metastasis site 2. V1: Visit 1; V2: Visit 2. 
Figure 2. Gene expression analysis. Heatmap depicting RT-PCR expression levels of a panel of 
genes implicated in TNBC biology from CTCs isolated at Visit 1 (V1, 5 CTCs counted by 
CellSearch) and Visit 2 (V2, 969 CTCs counted by CellSearch), primary tumor and metastatic 
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grey) account for 0 to 33.3 percentiles; medium level (dark grey) for 33.3 to 66.6 and high level 
(black) for 66.6 to 100 percentile]. 
 
Figure 3. CDX generation. A) Tumor growth evaluated by in vivo imaging 5 months after CTCs 
injection and tumor development of CDX1. B) Scheme of mammary fat pad distribution in 
mice. Orthotopic injection of tumor cells disaggregated from CDX1 leads to tumor growth in 
the mammary fad pat (CDX2M). In vivo image of tumor tracking using 2-DG-750. C) CTCs 
cluster obtained after processing CDX2M mouse blood using CellSearch. D) Macroscopic image 
of CDX growth after subcutaneous implantation of part of CDX1 tumor (passage 2: CDX2).  
Figure 4. CDX Characterization. A) Histological characterization of CDX1 paraffin-embedded 
samples. Haematoxilin-eosin staining and immunohistochemical analysis of indicated markers 
(Scale bar: 100 µm). B) Gene expression analysis of CDX1 samples by qRT-PCR. 40-ct 
normalized by B2M is represented.  
Figure 5. RNA sequencing analysis. A) Clustered heat map depicting RNA-normalized 
expression levels for genes Fold Change ǀ2ǀ to normal sample. B) Principal Components 
Analysis of indicate samples: normal tissue (N, in black); primary tumor (PT, in blue); 
metastatic sites (M1 and M2, in red and brown respectively); and CDX1, 2 and 2M (in green).  
Figure 6. Venn Diagram analysis. A) Overlapping up-regulated common genes between CDX 
and metastasis. Grey scale represents percentage of similarity (being darker more similar) B) 
Gene ontology analysis denoting the main pathways associated to those common up regulated 
genes (from diagram A). C) Venn Diagrams showing common down regulated genes between 
CDX and metastasis. D) Gene ontology analysis denoting the main pathways associated to 
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Figure 7. GO analysis. Gene ontology analysis denoting the main pathways associated to CDX 
common genes (CDX, dark grey), metastasis common genes (Metastasis, black) and shared 
genes among CDX and metastasis (CDX+M, in light grey). 
 
Figure 8. Validation of RNA-sequencing results in CTCs from TNBC patients. A) Gene 
expression levels of AURKB, HIST1H4A1, MELK, MYCL and PCDHA8 genes in a cohort of 32 
patients (grey) and 22 controls (white) analyzed by qRT-PCR. *p≤0,05; ** p≤0,01; *** p≤0,001. 
B and C) Survival curves for progression free survival (PFS) and overall survival (OS) in a cohort 
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